全球首创心肌肌球蛋白抑制剂迈凡妥®（玛伐凯泰胶囊）在中国获批用于治疗梗阻性肥厚型心肌病成人患者

[2] Olivotto I, et al. Lancet 2020; 396: 759–69.；Tian Z, et al. JAMA Cardiol. 2023 Oct 1;8(10):957-965.

[3] 国家心血管病专家委员会心力衰竭专业委员会, 中国医师协会心力衰竭专业委员会, 中华医学会心血管分会心力衰竭学组, 等. 中国肥厚型心肌病指南 2022[J]. 中华心力衰竭和心肌病杂志, 2022, 6(2): 80-105. DOI: 10.3760/cma.j.cn1101460-20220805-00070.

[4] Zou, Y. , Song, L. , Wang, Z. , Ma, A. , Liu, T. , Gu, H. , et al. (2004). Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. American Journal of Medicine, 116(1), 14-18.

[5] Maron M, et al. Heart. 2022 Oct 21:heartjnl-2020-316693

[6] Butzner, Michael et al. “Clinical Characteristics and Healthcare Resource Utilization among Patients with Obstructive Hypertrophic Cardiomyopathy Treated in a Range of Settings in the United States.” Journal of clinical medicine vol. 11,13 3898. 4 Jul. 2022

[7] Zhuang Tian,et al. JAMA Cardiol. Published online August 28, 2023. doi:10.1001/jamacardio.2023.3030 (https://jamanetwork.com/journals/jamacardiology/fullarticle/2809051)

[8] Arbelo E, et al; ESC Scientific Document Group. Eur Heart J. 2023 Oct 1;44(37):3503-3626.

[9] 国家心血管病中央心肌病专科同盟, 等. 中国循环杂志,2023,38(1):1-33.

[10] 国家心血管病专家委员会心力衰竭专业委员会,等. 中华心力衰竭和心肌病杂志, 2022, 06(2): 80-105.